Search ↗

Comparison

BPC-157 vs LL-37

Both are healing & repair, so the meaningful differences are in kinetics, evidence and regulatory status.

On published evidence alone, LL-37 is the better documented of the two (preliminary human). That is a statement about the state of the literature, not a recommendation.

BPC-157 LL-37
Class Healing & repair Healing & repair
Evidence Animal models only Preliminary human
Human trials None published ~3
Half-life ~4 hours ~1 hour
Reported range 200-500 mcg 100-500 mcg
Frequency 1-2x daily, often near the injury site Once daily, short courses
Routes Subcutaneous, Oral, Intramuscular Subcutaneous, Topical
FDA approved No No
Research use only Yes Yes
Banned in sport Yes No
Studied for Tendon and ligament injury research, Gastrointestinal healing research, Soft tissue repair Antimicrobial research, Biofilm research, Wound healing
Reported side effects Injection-site reactions, Transient nausea, Headache, Dizziness Injection-site inflammation, Flu-like symptoms, Flushing

BPC-157

BPC-157 is a stable 15-amino-acid sequence derived from body protection compound, a protein found in human gastric juice. Animal work reports accelerated healing across tendon, ligament, muscle, bone and gastrointestinal tissue, with proposed mechanisms including upregulation of VEGF-driven angiogenesis, modulation of the nitric oxide system, and increased fibroblast migration and growth-factor receptor expression. The evidence base is almost entirely rodent. No adequately powered human trial has been published, which is the central fact about this compound and should lead every page about it.

LL-37

LL-37 is the active 37-residue fragment cleaved from human cathelicidin hCAP18, produced by neutrophils and epithelial cells. It disrupts bacterial membranes directly and also modulates host immunity by recruiting immune cells, neutralising endotoxin and influencing wound repair. Its biology is genuinely double-edged: the same peptide is implicated in the pathology of rosacea and psoriasis, so more is not straightforwardly better.

BPC-157 vs LL-37: common questions

What is the difference between BPC-157 and LL-37?

Both are healing & repair. BPC-157: A synthetic pentadecapeptide derived from a gastric protein, and the most searched compound in the peptide category. LL-37: The only human cathelicidin antimicrobial peptide, with broad antibacterial activity and a complicated immunomodulatory profile.

Which has stronger evidence, BPC-157 or LL-37?

LL-37 has the stronger evidence base (preliminary human, about 3 human studies) compared with BPC-157 (animal models only).

Are BPC-157 and LL-37 FDA approved?

Neither is FDA approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 9941957) ↗ · structure, identifiers, synonyms
  2. WADA Prohibited List ↗ · current year
  3. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
  4. CAS Registry Number 137525-51-0 ↗ · chemical identity
  5. PubChem compound record (CID 16198951) ↗ · structure, identifiers, synonyms
  6. CAS Registry Number 154947-66-7 ↗ · chemical identity

Published literature

  1. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.Cell Tissue Res 2019.PubMed 30915550 · doi:10.1007/s00441-019-03016-8
  2. Seiwerth S, Rucman R, Turkovic B, et al.. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.Curr Pharm Des 2018.PubMed 29998800 · doi:10.2174/1381612824666180712110447
  3. Mayfield CK, Bolia IK, Feingold CL, et al.. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.Am J Sports Med 2026.PubMed 41476424 · doi:10.1177/03635465251357593
  4. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
  5. DeFoor MT, Dekker TJ. Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?.Arthroscopy 2025.PubMed 39265666 · doi:10.1016/j.arthro.2024.09.005
  6. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
  7. Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.Int J Mol Sci 2026.PubMed 42123471 · doi:10.3390/ijms27093890
  8. Seiwerth S, Brcic L, Vuletic LB, et al.. BPC 157 and blood vessels.Curr Pharm Des 2014.PubMed 23782145 · doi:10.2174/13816128113199990421
  9. Ahn CS, Huang WW. Rosacea Pathogenesis.Dermatol Clin 2018.PubMed 29499802 · doi:10.1016/j.det.2017.11.001
  10. Ismailova A, White JH. Vitamin D, infections and immunity.Rev Endocr Metab Disord 2022.PubMed 34322844 · doi:10.1007/s11154-021-09679-5
  11. Malhotra S, Hayes D Jr, Wozniak DJ. Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface.Clin Microbiol Rev 2019.PubMed 31142499 · doi:10.1128/CMR.00138-18
  12. Wang H, Zhou C. Advances in the pathogenesis of rosacea.Front Immunol 2025.PubMed 41646975 · doi:10.3389/fimmu.2025.1705588
  13. Takahashi T, Yamasaki K. Psoriasis and Antimicrobial Peptides.Int J Mol Sci 2020.PubMed 32947991 · doi:10.3390/ijms21186791
  14. Traidl S, Roesner L, Zeitvogel J, et al.. Eczema herpeticum in atopic dermatitis.Allergy 2021.PubMed 33844308 · doi:10.1111/all.14853
  15. Scheenstra MR, van Harten RM, Veldhuizen EJA, et al.. Cathelicidins Modulate TLR-Activation and Inflammation.Front Immunol 2020.PubMed 32582207 · doi:10.3389/fimmu.2020.01137
  16. Kwiecien K, Zegar A, Jung J, et al.. Architecture of antimicrobial skin defense.Cytokine Growth Factor Rev 2019.PubMed 31473081 · doi:10.1016/j.cytogfr.2019.08.001

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.